effect overlay
activetrials
Dementia

A Phase IIa Study of ANAVEX2-73 Adaptive Trial Design with repeated doses, Maximum Tolerated Dose Finding, Pharmacodynamic Investigation and Bioavailability Evaluation in Patients with Mild to Moderate Alzheimer’s Disease With a 52 week Open Label Follow-Up period 
 

HREC: 2016.097
Principal Investigator: Dr Christopher Kyndt
Coordinator contact: Lauren Martell
Funding: Commercial
Dementia

Deferiprone to Delay Dementia (The 3D Study): a clinical proof of cencept study
 

HREC: 2017.172
Principal Investigator: Dr Christopher Kyndt
Coordinator contact: Lauren Martell
Funding: Commercial

A Multicentre, Randomised, Double-Blind, Placebo Controlled Trial to Evaluate the Effectiveness and Safety of Sailuotong (SLT), a Standardised Herbal Medicine Formula in Patients with Vascular Dementia and Alzheimer's Disease with Cerebrovascular Disease
 

HREC: 2018.225
Principal Investigator: A/Prof Nawaf Yassi
Coordinator contact: Sophie Robinson
Funding: Non-Commercial
Dementia

Phase 3b open-label, multicenter, safety study of BIIB037 (aducanumab) in subjects with Alzheimer’s disease who had previously participated in the Aducanumab studies 221AD103, 221AD301, 221AD302 and 221AD205
 

HREC: 2020.071
Principal Investigator: A/Prof David Darby
Coordinator contact: Lauren Martell
Funding: Commercial

A Phase 2b Randomised Controlled Trial of Sodium Selenate as a Disease Modifying Treatment for Probably Behavioural Variant Fronto-temporal Dementia
 

HREC: 2020.171
Principal Investigator: Prof Dennis Velakoulis
Coordinator contact: Lauren Martell
Funding: Non-Commercial